Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$0.21 - $5.63 $21,093 - $565,510
100,446 New
100,446 $26,000
Q3 2021

Nov 15, 2021

BUY
$0.93 - $1.18 $36,157 - $45,877
38,879 Added 68.27%
95,832 $108,000
Q2 2021

Aug 16, 2021

SELL
$1.19 - $2.06 $251 - $434
-211 Reduced 0.37%
56,953 $67,000
Q1 2021

May 17, 2021

BUY
$1.62 - $3.05 $92,605 - $174,350
57,164 New
57,164 $118,000
Q3 2020

Nov 16, 2020

SELL
$0.8 - $2.33 $50,669 - $147,575
-63,337 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$0.75 - $1.29 $28,122 - $48,371
37,497 Added 145.11%
63,337 $52,000
Q2 2018

Aug 10, 2018

BUY
$16.51 - $19.85 $426,618 - $512,924
25,840 New
25,840 $0

Others Institutions Holding ECOR

About electroCore, Inc.


  • Ticker ECOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 71,176,896
  • Market Cap $798M
  • Description
  • electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults....
More about ECOR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.